Company: CSCIF
Filing Date: 2025-04-09
Form Type: 20-F
Source: 0001641172-25-003456
Chunk: 66

Company: COSCIENS Biopharma Inc.
Filing Date: 2025-04-09
Form: 20-F
Item: Item 5
Chunk 66
---
, a significant change in the market price
or value of our securities, or where it is likely that a reasonable investor would consider the information and disclosures to be important
in making an investment decision.

We
are a reporting issuer under the securities legislation of all of the provinces of Canada, and our securities are registered with the
U. S. Securities and Exchange Commission (“ SEC”). We are therefore required to file or furnish continuous disclosure information,
such as interim and annual financial statements, management’s discussion and analysis, proxy or information circulars, annual reports
on Form 20-F, material change reports and press releases with the appropriate securities regulatory authorities. Additional information
about the Company and copies of these documents may be obtained free of charge upon request from our Corporate Secretary or on the Internet
at the following addresses: www. cosciensbio. com, www. sedarplus. ca and www. sec. gov.

Company
Overview

COSCIENS
Biopharma Inc. is a Life Science company developing and commercializing a diversified portfolio of products for the cosmeceutical, nutraceutical
and pharmaceutical markets. Such products being produced using the Company’s proprietary technologies. The Company’s patented
technologies include the Pressurized Gas eXpanded (PGX) technology, which is a unique and disruptive technology that generates high-value
yields of active ingredients from natural based resources for use in novel cosmeceutical, nutraceutical and therapeutics products. The
Company’s two value-driving products, oat beta glucan and avenanthramides, are found in many household name cosmetic and personal
care brands. These products are manufactured from the Company’s proprietary oat extraction manufacturing technology and are known
for their well-documented health benefits.

On August 27, 2024, the Company announced that the Phase 3 DETECT-trial evaluating macimorelin for the diagnosis
of Childhood Onset Growth Hormone Deficiency (CGHD) had failed to meet its primary endpoints according to the definitions in the study
protocol. Following these results, the Company initiated a strategic review of its pipeline. As part of this realignment, the Company
has discontinued investment in its pre-clinical programs and ceased all further development related to macimorelin. The Company is exploring
and validating strategic alternatives for macimorelin, including, but not limited to, potential divestment of the asset.

Plan
of Arrangement

On
June 3, 2024, A